R&D | May 28, 2026
Novo Nordisk to showcase late-stage pipeline & semaglutide expansion at ADA 2026
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
American College of Cardiology and Korean Society of Cardiology convene global experts to address rising cardiometabolic burden
With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
